Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

Core Insights - Zymeworks Inc. reported a disappointing 4Q25 earnings, with GAAP EPS at -$0.55, missing consensus expectations by approximately $0.21 [1] - Revenue for the quarter was only $2.52 million, significantly below estimates, indicating a challenging financial performance [1] Company Overview - Zymeworks is involved in the biotechnology sector, focusing on drug development and innovative therapeutic solutions [1] - The company aims to leverage unique mechanisms of action and first-in-class therapies to reshape treatment paradigms [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis [1] - The focus is on identifying promising biotechnology companies and evaluating the science behind drug candidates, competitive landscape, and market opportunities [1]